We caught up with our Head of Peptide Science, Peter Timmerman, Ph.D., to learn more about Peter, his expertise, and his role at Biosynth.
What is your background, and how did you become interested in peptides?
My journey into peptides started during my time at the Free University of Amsterdam (VUA). I was studying organic chemistry there and became fascinated with the typical organic molecules that could be used in flavoring and drugs. It was during this period that I joined a research group at Twente University (close to the German border), where we delved into the intriguing world of supramolecular chemistry. This branch of chemistry focuses on the interactions between molecules beyond their levels.
As I delved deeper into supramolecular chemistry, I found myself increasingly drawn to peptides. Their role in the origin of life and biological molecules fascinated me, and it perfectly aligned with my growing curiosity about drug development. That’s when I joined Biosynth at the Lelystad site, formerly known as Pepscan, and I’ve been there ever since, exploring the incredible potential of peptides.
What are your areas of specialization?
My specialization lies in supramolecular chemistry, where I specifically examine the interactions between molecules beyond their singular levels. Additionally, I’ve focused a lot on cyclic peptides. These are interesting compared with linear peptides as cyclic peptides are more stable and have higher binding affinities, higher specificities, and improved proteolytic stabilities, making them desirable drug candidates. To address this challenge, our site developed and patented the CLIPS™ technology, which enables the cyclization of peptides, making them more stable and viable as potential drugs. This groundbreaking technology, known as CLIPS™, has gained worldwide recognition and is now utilized by numerous research groups.
What does your average day look like?
As the Head of Peptide Science, my day-to-day work involves more supervisory tasks and project management. However, I still make time to visit the labs every few weeks, as I value staying connected with the scientific process. Although I do miss the hands-on work in the lab, I find that my creativity is best utilized in developing new ideas and managing teams.
I’m actively involved in peptide discovery projects as well. Once we identify potential binders through our discovery platform, our focus shifts to optimizing their affinity. My contribution to these projects is specifically aimed at optimizing the target binding affinity of these molecules. Additionally, I’m engaged in Immunogen Design projects, which utilize the CLIPS™ technology in a more design-based approach. Customers approach us intending to identify mimics of specific proteins, and we research and work on creating effective and innovative solutions.
Which projects do you find most interesting?
I’m incredibly passionate about seeing projects come to fruition and the hard work that goes into achieving that success. There’s a profound sense of personal fulfillment that comes from making projects thrive and going the extra mile to ensure our customers are satisfied. One challenge I particularly enjoy is optimizing lead peptides identified for customers via our Peptide Discovery platform; the success that comes from overcoming this challenge is immensely rewarding.
We’ve heavily invested in patentable technologies for contracted research work. When these technologies are prioritized and patented, they can be used for milestone payments, ultimately contributing to the company’s profitability. Additionally, we’ve built a state-of-the-art display screening platform aimed at identifying peptide binders. This platform plays a crucial role in defining target proteins and identifying the affinity protein modules that bind to them. These proteins can then be patented and utilized in the development of drugs and drug therapy.
As an innovator and researcher, I derive great satisfaction from developing new ideas and technologies. I’m always on the lookout for innovative projects that push the boundaries of science. Even when faced with projects that may not seem particularly challenging, I find ways to infuse excitement and engagement through my creativity.
What is your focus for the next few years?
Looking ahead, my primary goal is to file for an advanced CLIPS™ patent. This objective is especially meaningful as it coincides with the 20th anniversary of the original CLIPS™ patent filing this year (2024), representing a significant milestone in our history.
I also look forward to continuing to spur innovation and shape the direction of peptide research with my enthusiasm for learning and commitment to the field.
Peter’s enthusiasm for the topic of Peptide Discovery was evident during a recent webinar he presented. He delves into the challenges researchers face and presents Biosynth’s innovative CLIPSTM technology as a potential solution. Visit our website to view the webinar.
You can read more from our experts in our ‘Meet the Experts’ blog series here.
Leave a Reply